PuSH - Publikationsserver des Helmholtz Zentrums München

Petersen, J.* ; Finan, B.* ; Johansen, V.B.I.* ; Müller, T.D. ; Clemmensen, C.*

The evolving landscape of obesity pharmacotherapy.

Nat. Rev. Drug Discov., DOI: 10.1038/s41573-026-01427-1 (2026)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Obesity is a chronic, relapsing disease driven by complex interactions between genetic, environmental, neuroendocrine and behavioural factors. The advent of incretin-based therapies and the expansion to multi-receptor agonist peptides targeting glucagon-like peptide 1 (GLP1), glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin receptors has transformed obesity treatment, demonstrating average weight loss of more than 20% in humans and improvements in a broad range of obesity-related comorbidities. In this Review, we trace the recent evolution of obesity pharmacotherapy from GLP1 receptor agonists to next-generation multi-receptor agonists, alongside strategies that incorporate oral formulations, weight-loss quality approaches and tissue-specific drug targeting. We outline major translational and biological challenges, identify key gaps for future research and discuss emerging approaches aimed at achieving durable and scalable obesity treatment.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Amylin ; Pharmacotherapy ; Obesity ; Translational Research ; Disease ; Translational Medicine ; Human Obesity ; Agonist
ISSN (print) / ISBN 1474-1776
Zeitschrift Nature Reviews - Drug Discovery
Verlag Nature Publishing Group
Verlagsort London
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)